Logo image of ATRA

ATARA BIOTHERAPEUTICS INC (ATRA) Stock Overview

NASDAQ:ATRA - US0465132068 - Common Stock

12.05 USD
-0.31 (-2.51%)
Last: 8/29/2025, 8:07:13 PM
12.06 USD
+0.01 (+0.08%)
After Hours: 8/29/2025, 8:07:13 PM

ATRA Key Statistics, Chart & Performance

Key Statistics
52 Week High18.7
52 Week Low5.01
Market Cap84.59M
Shares7.02M
Float5.52M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.43
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10
IPO10-16 2014-10-16
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ATRA short term performance overview.The bars show the price performance of ATRA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

ATRA long term performance overview.The bars show the price performance of ATRA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 -50

The current stock price of ATRA is 12.05 USD. In the past month the price increased by 4.33%. In the past year, price increased by 58.55%.

ATARA BIOTHERAPEUTICS INC / ATRA Daily stock chart

ATRA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About ATRA

Company Profile

ATRA logo image Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in Thousand Oaks, California and currently employs 153 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.

Company Info

ATARA BIOTHERAPEUTICS INC

1280 Rancho Conejo Blvd

Thousand Oaks CALIFORNIA 94080 US

CEO: Pascal Touchon

Employees: 153

ATRA Company Website

ATRA Investor Relations

Phone: 18056234211

ATARA BIOTHERAPEUTICS INC / ATRA FAQ

What is the stock price of ATARA BIOTHERAPEUTICS INC today?

The current stock price of ATRA is 12.05 USD. The price decreased by -2.51% in the last trading session.


What is the ticker symbol for ATARA BIOTHERAPEUTICS INC stock?

The exchange symbol of ATARA BIOTHERAPEUTICS INC is ATRA and it is listed on the Nasdaq exchange.


On which exchange is ATRA stock listed?

ATRA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ATARA BIOTHERAPEUTICS INC stock?

10 analysts have analysed ATRA and the average price target is 16.83 USD. This implies a price increase of 39.67% is expected in the next year compared to the current price of 12.05. Check the ATARA BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ATARA BIOTHERAPEUTICS INC worth?

ATARA BIOTHERAPEUTICS INC (ATRA) has a market capitalization of 84.59M USD. This makes ATRA a Micro Cap stock.


How many employees does ATARA BIOTHERAPEUTICS INC have?

ATARA BIOTHERAPEUTICS INC (ATRA) currently has 153 employees.


What are the support and resistance levels for ATARA BIOTHERAPEUTICS INC (ATRA) stock?

ATARA BIOTHERAPEUTICS INC (ATRA) has a support level at 11.7 and a resistance level at 12.35. Check the full technical report for a detailed analysis of ATRA support and resistance levels.


Is ATARA BIOTHERAPEUTICS INC (ATRA) expected to grow?

The Revenue of ATARA BIOTHERAPEUTICS INC (ATRA) is expected to grow by 3.06% in the next year. Check the estimates tab for more information on the ATRA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ATARA BIOTHERAPEUTICS INC (ATRA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ATARA BIOTHERAPEUTICS INC (ATRA) stock pay dividends?

ATRA does not pay a dividend.


When does ATARA BIOTHERAPEUTICS INC (ATRA) report earnings?

ATARA BIOTHERAPEUTICS INC (ATRA) will report earnings on 2025-11-10.


What is the Price/Earnings (PE) ratio of ATARA BIOTHERAPEUTICS INC (ATRA)?

ATARA BIOTHERAPEUTICS INC (ATRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.43).


What is the Short Interest ratio of ATARA BIOTHERAPEUTICS INC (ATRA) stock?

The outstanding short interest for ATARA BIOTHERAPEUTICS INC (ATRA) is 3.82% of its float. Check the ownership tab for more information on the ATRA short interest.


ATRA Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ATRA. When comparing the yearly performance of all stocks, ATRA is one of the better performing stocks in the market, outperforming 93.13% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ATRA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ATRA. ATRA has a medium profitability rating, but doesn't score so well on its financial health evaluation.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ATRA Financial Highlights

Over the last trailing twelve months ATRA reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 98.91% compared to the year before.


Industry RankSector Rank
PM (TTM) 3.07%
ROA 15.7%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%106.13%
Sales Q2Q%-38.63%
EPS 1Y (TTM)98.91%
Revenue 1Y (TTM)202.4%

ATRA Forecast & Estimates

10 analysts have analysed ATRA and the average price target is 16.83 USD. This implies a price increase of 39.67% is expected in the next year compared to the current price of 12.05.

For the next year, analysts expect an EPS growth of 91.7% and a revenue growth 3.06% for ATRA


Analysts
Analysts80
Price Target16.83 (39.67%)
EPS Next Y91.7%
Revenue Next Year3.06%

ATRA Ownership

Ownership
Inst Owners51.11%
Ins Owners3.06%
Short Float %3.82%
Short Ratio3.93